What are the symptoms of a metastatic neuroendocrine tumor of the abdomen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms of Metastatic Neuroendocrine Tumors of the Abdomen

Metastatic neuroendocrine tumors (NETs) of the abdomen commonly present with symptoms related to hormone hypersecretion (functional tumors) or mass effect from the primary tumor and metastases (non-functional tumors), with approximately 60% of patients presenting with metastatic disease at diagnosis. 1, 2

Functional Tumor Symptoms

Carcinoid Syndrome (Small Intestinal NETs)

  • Flushing (especially of face and upper chest)
  • Diarrhea (often watery and frequent)
  • Abdominal cramping
  • Wheezing or difficulty breathing
  • Endocardial fibrosis (right-sided heart valve disease)
  • Occurs in approximately 30% of patients with metastatic small intestinal NETs 1
  • Caused by serotonin and peptide hormones released from liver metastases 1

Pancreatic NET Syndromes

Based on specific hormone production 1:

  • Insulinoma: Confusion, sweating, dizziness, weakness, unconsciousness, relief with eating
  • Gastrinoma (Zollinger-Ellison syndrome): Severe peptic ulceration, diarrhea
  • Glucagonoma: Necrolytic migratory erythema (distinctive rash), weight loss, diabetes mellitus, stomatitis, diarrhea
  • VIPoma (Werner-Morrison syndrome): Profuse watery diarrhea with marked hypokalemia
  • Somatostatinoma: Cholelithiasis, weight loss, diarrhea, steatorrhea, diabetes mellitus

Non-Functional Tumor Symptoms

Non-functional tumors (approximately 30-40% of cases) may present with 1, 2:

  • Abdominal pain (often vague and chronic)
  • Change in bowel habits (often misdiagnosed as irritable bowel syndrome)
  • Weight loss
  • Nausea and vomiting
  • Jaundice (if bile duct obstruction)
  • Palpable abdominal mass
  • Hepatomegaly (from liver metastases)
  • Ascites (in advanced disease)
  • Fatigue and weakness

Symptoms Related to Metastatic Disease

  • Liver metastases: Right upper quadrant pain, early satiety, weight loss, hepatomegaly
  • Mesenteric metastases: Abdominal pain, bowel obstruction, ischemia due to mesenteric fibrosis
  • Peritoneal metastases: Ascites, abdominal distention, bowel obstruction
  • Bone metastases: Bone pain, pathological fractures

Carcinoid Crisis

A potentially life-threatening complication characterized by 1:

  • Profound flushing
  • Bronchospasm
  • Tachycardia
  • Widely and rapidly fluctuating blood pressure
  • Usually precipitated by anesthesia, tumor manipulation during surgery, or invasive procedures

Laboratory Abnormalities

Biochemical markers that may be elevated include 1, 2:

  • Chromogranin A (general NET marker)
  • 5-HIAA in 24-hour urine (for carcinoid tumors)
  • Specific hormones based on tumor type (insulin, gastrin, glucagon, VIP, etc.)
  • Neuron-specific enolase (especially in poorly differentiated tumors)

Important Clinical Considerations

  • Symptoms may be intermittent and vague, leading to delays in diagnosis
  • Many patients are initially misdiagnosed with irritable bowel syndrome or other functional disorders 1
  • The presence of a genetic syndrome (MEN1, MEN2, NF1) should be thoroughly investigated in all patients with NETs 1, 2
  • Metastatic disease may be the first presentation, with an occult primary tumor 3

Early recognition of these symptoms is crucial as the 5-year survival rate for metastatic NETs ranges from 25-75% depending on tumor type, grade, and treatment center expertise 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Abdominal Neuroendocrine Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Surgery for metastatic neuroendocrine tumors with occult primaries.

The Journal of surgical research, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.